Browse > Article
http://dx.doi.org/10.24304/kjcp.2019.29.1.18

Formulation of the Scope and Key Questions of the Guideline Recommendations for Immunosuppressive Treatment in Kidney Transplantation  

Huh, Seungyeon (College of Pharmacy & Research Institute of Pharmaceutical Science, Seoul National University)
Han, Nayoung (College of Pharmacy & Research Institute of Pharmaceutical Science, Seoul National University)
Sohn, Minji (College of Pharmacy & Research Institute of Pharmaceutical Science, Seoul National University)
Ryu, Junghwa (Transplantation Center, Seoul National University Hospital)
Yang, Jaeseok (Transplantation Center, Seoul National University Hospital)
Oh, Jung Mi (College of Pharmacy & Research Institute of Pharmaceutical Science, Seoul National University)
Publication Information
Korean Journal of Clinical Pharmacy / v.29, no.1, 2019 , pp. 18-24 More about this Journal
Abstract
Background: Although a growing number of guidelines and clinical researches are available for immunosuppressive treatment of post-transplantation, there is no clinical practice guideline for the care of kidney transplant recipients in Korea. Selection of a researchable question is the most important step in conducting qualified guideline development. Thus, we aimed to formulate key questions for Korean guideline to aid clinical decision-making for immunosuppressive treatment. Methods: Based on previous published guidelines review, a first survey was constructed with 29 questions in the range of immunosuppressive treatments. The experts were asked to rate the clinical importance of the question using a 5-point Likert scale. The questions reached 60% or more from the first survey and additional new questions were included in the second survey. In analyzing the responses to items rated on the 9-point scale, consensus agreement on each question was defined as 75% or more of experts rating 7 to 9. Results: In the first survey, 50 experts were included. Among the 29 questions, 27 were derived to get 60% or more importance and 3 new questions were additionally identified. Through the second survey, 9 questions were selected that experts reached consensus on 75% and over of the options. Finally, we developed key questions using PICO (patient, intervention, comparison, and outcome) methodology. Conclusion: The experts reached a high level of consensus on many of key questions in the survey. Final key questions provide direction for developing clinical practice guideline in the immunosuppressive treatment of transplantation.
Keywords
Kidney transplantation; clinical guideline; evidence-based; key questions;
Citations & Related Records
연도 인용수 순위
  • Reference
1 BC Transplant Society. Clinical Guidelines for Kidney Transplantation [Internet]. Canada: Provincial Health Services Authority, c2018 [cited 2018 Dec 10]. Available from: http://www.transplant.bc.ca/health-professionals/transplant-clinical-guidelines/guidelines-for-transplant.
2 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9 Suppl 3:S1-155.
3 Woolf S, Schünemann HJ, Eccles MP, et al. Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations. Implement Sci 2012;7:61.   DOI
4 Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993;270(11):1339-43.   DOI
5 Kim SI, Kim YS, Kim MS, et al. A renal transplantation and hemodialysis cost-utility analysis in patients with end-stage renal disease. J Korean Soc Transplant 2010;24(3):173-81.   DOI
6 Korean Network for Organ Sharing (KONOS). Annual report of the transplant 2017 [Internet]. Seoul (KR): Korean Network for Organ Sharing, c2018 [cited 2018 Dec 10]. Available from: http://www.konos.go.kr.
7 Kim SH, Jo MW, Go DS, et al. Economic burden of chronic kidney disease in Korea using national sample cohort. J Nephrol 2017;30(6):787-93.   DOI
8 Legendre C, Canaud G, Martinez F. Factors influencing long-term outcome after kidney transplantation. Transpl Int 2014 Jan;27(1):19-27.   DOI
9 Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999;353(9158):1083-91.   DOI
10 Kalluri HV and Hardinger KL. Current state of renal transplant immunosuppression: Present and future. World J Transplant 2012;2(4):51-68.   DOI
11 Field MJ and Lohr KN. Clinical practice guideline: directions for a new program. Washington D.C.: National Academy Press 1990;8-18.
12 Yoon HE and Yang CW. Renal transplantation in highly sensitized recipients. J Korean Soc Transplant 2008;22:8-12.
13 Woolf SH, Grol R, Hutchinson A, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999;318(7182):527-30.   DOI
14 Entwistle VA, Watt IS, Davis H, et al. Developing information materials to present the findings of technology assessments to consumers. The experience of the NHS Centre for Reviews and Dissemination. Int J Technol Assess Health Care 1998;14(1):47-70.   DOI
15 Lee S and Kang DH. ABO-incompatible kidney transplantation. Ewha Med J 2015;38(1):7-13.   DOI
16 Yu H, Kim YJ, Kwon SW, et al. ABO incompatible living donor kidney transplantation with rituximab and plasmapheresis: A single center experience. Korean J Nephrol 2011;30:386-93.
17 Karuthu S and Blumberg EA. Common infections in kidney transplant recipients. Clin J Am Soc Nephrol 2012;7(12):2058-70.   DOI
18 Silkensen JR. Long-term complications in renal transplantation. J Am Soc Nephrol 2000;11(3):582-8.   DOI
19 Baker RJ, Mark PB, Patel RK, et al. Renal association clinical practice guideline in post-operative care in the kidney transplant recipient. BMC Nephrol 2017;18(1):174.   DOI